BUZZ-Intellia公司暂停基因编辑疗法后期试验后业绩下滑

路透中文
Oct 27
BUZZ-<a href="https://laohu8.com/S/NTLA">Intellia</a>公司暂停基因编辑疗法后期试验后业绩下滑

10月27日 - ** 基因编辑公司Intellia TherapeuticsNTLA.O股价盘前下跌60%至61.02美元

** 该公司暂停了 (link) 其名为nex-z的实验性基因编辑疗法在一种蛋白质堆积疾病的后期试验中的患者用药。

** NTLA称,在后期试验中,一名服药患者出现严重肝脏副作用,因此暂停服药

** 公司就下一步行动咨询专家和监管机构 - NTLA

** 据估计,迄今已有 450 多名患者接受了 nex-z 治疗,公司称

** 截至上一交易日收盘,公司股价累计下跌 120

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10